Thursday, November 12, 2026

USD/CNH Falls By 2% In The Last 21 Sessions

ViaNews Editorial Team

December 20, 2023

USD/CNH Falls By 2% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.61% for the last 21 sessions. At 04:14 EST on Wednesday, 20 December, USD/CNH (USDCNH) is $7.12.

USD/CNH's yearly highs and lows, it's 0.052% up from its 52-week low and 0.014% down from its 52-week high.

News about

  • Usd/jpy rallies nearing 145.00 fuelled by a dovish boj. According to FXStreet on Tuesday, 19 December, "This has boosted the USD/JPY about 1.25% higher on the day so far, to reach intra-day highs near 145.00."
  • According to FXStreet on Tuesday, 19 December, "The Japanese Yen (JPY) comes under heavy selling pressure and pushes the USD/JPY pair higher for the third straight day after the Bank of Japan (BoJ) announced its policy decision earlier this Tuesday. ", "Meanwhile,oscillators on the daily chart are holding deep in the negative territory and suggest that the path of least resistance for the USD/JPY pair is to the downside. "
  • Usd/jpy: the pace of depreciation will be gradual in the near term, decisive break below 140 in 2Q24 – ING. According to FXStreet on Tuesday, 19 December, "We remain bearish on USD/JPY in 2024, as the oversold Yen can still benefit from the end of negative rates in Japan and we see the Fed cut rates by 150 bps, but the pace of depreciation in the pair will be gradual in the near term, and we only see a decisive break below 140 in 2Q24."
  • Usd/jpy edges higher ahead of boj decision, rising US yields. According to FXStreet on Monday, 18 December, "In Monday 's session, the USD/JPY pair is making notable strides upward, trading around the 143.00 level. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com